Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail

NCT06910098 is registered in ClinicalTrials.gov with Central Park Medical College as lead sponsor.

NCT NCT06910098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06910098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail
Lead sponsor
Central Park Medical College
Phase
Not applicable
Overall status
Completed
Start date
December 1, 2023
Completion date
August 31, 2024
Enrollment
195 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ldl - low density lipoprotein receptor disorder, rosuvastatin